PETX News Alert Aratana Therapeutics Inc (PETX) 17.05 12/25/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Aratana Therapeutics Inc (PETX) 17.05 $PETX

Rewards Outweigh Risk for Long-Term Equity Players: Featured Research on Pier 1 Imports, CarMax, Transocean, Enanta and Aratana
PR Newswire - Mon Dec 22, 8:10AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Pier 1 Imports (NYSE: PIR), CarMax (NYSE: KMX), Transocean (NYSE: RIG), Enanta (NASDAQ: ENTA), and Aratana (NASDAQ: PETX). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
KMX: 67.61 (-0.15), RIG: 18.77 (-0.37), PIR: 15.33 (-0.11), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06)

Nasdaq stocks posting largest percentage increases
AP - Fri Dec 19, 5:41PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
IMDZ: 34.96 (+0.78), OFLX: 34.45 (unch), INGN: 29.99 (-0.09), PETX: 17.05 (+0.42), HGSH: 4.60 (-0.06), NYNY: 7.89 (+0.32), SNFCA: 5.08 (-0.36)

S&P 500 Falls Just Short of Record Entering Final Weeks of Year
at The Street - Fri Dec 19, 3:06PM CST
The Federal Reserve triggers a three-day rally which sees major indexes jump more than 3% over the past five sessions.
KMX: 67.61 (-0.15), KMI: 42.01 (+0.10), NKE: 96.29 (+0.32), BBRY: 10.67 (-0.13), RHT: 70.92 (+0.47), PETX: 17.05 (+0.42), CVX: 113.47 (-0.48), SLB: 87.06 (-0.26), FINL: 22.79 (+0.17), XLE: 80.13 (-0.59)

Stocks at Session Highs as Energy Sector Picks Up Steam
at The Street - Fri Dec 19, 2:04PM CST
Stocks are higher Friday, with the energy sector leading the S&P 500's gains.
KMI: 42.01 (+0.10), NKE: 96.29 (+0.32), BBRY: 10.67 (-0.13), IMGN: 5.90 (+0.13), PETX: 17.05 (+0.42), FINL: 22.79 (+0.17), SLB: 87.06 (-0.26), KMX: 67.61 (-0.15), APP: 1.06 (+0.01), RHT: 70.92 (+0.47), CVX: 113.47 (-0.48), XLE: 80.13 (-0.59), TNK: 4.74 (+0.04)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 11:45AM CST

RBY: 0.91 (+0.01), FATE: 4.90 (+0.23), IMDZ: 34.96 (+0.78), RXII: 1.60 (unch), GLMD: 5.95 (+0.15), TBIO: 2.31 (-0.09), SIM: 10.11 (+0.34), PHMD: 1.46 (-0.03), IMGN: 5.90 (+0.13), PETX: 17.05 (+0.42), NQ: 4.32 (-0.36), OTIC: 32.26 (+0.65), VHC: 5.98 (-0.19), FINL: 22.79 (+0.17), BBLU: 1.15 (-0.03), TRXC: 2.79 (+0.03), BAS: 7.30 (-0.08), ENRJ: 2.43 (+0.03), TNK: 4.74 (+0.04)

Energy Stocks Lead Market Gains as Crude Oil Prices Bounce
at The Street - Fri Dec 19, 10:11AM CST
Stocks were rising slightly, with energy stocks the leading gainers.
KMI: 42.01 (+0.10), NKE: 96.29 (+0.32), BBRY: 10.67 (-0.13), PETX: 17.05 (+0.42), XRX: 14.08 (+0.01), FINL: 22.79 (+0.17), SLB: 87.06 (-0.26), KMX: 67.61 (-0.15), RHT: 70.92 (+0.47), CVX: 113.47 (-0.48), XLE: 80.13 (-0.59)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 8:11AM CST

KMX: 67.61 (-0.15), MOLG: 2.92 (+0.03), CERS: 6.49 (+0.29), OREX: 5.98 (+0.01), APP: 1.06 (+0.01), ISIS: 59.49 (+1.88), PIR: 15.33 (-0.11), BBRY: 10.67 (-0.13), IMGN: 5.90 (+0.13), FMD: 5.06 (unch), RHT: 70.92 (+0.47), PETX: 17.05 (+0.42), NVGN: 2.40 (-0.09), TRXC: 2.79 (+0.03), NQ: 4.32 (-0.36), FINL: 22.79 (+0.17), TNK: 4.74 (+0.04)

Aratana up big on canine pain med trial results
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 7:58AM CST

PETX: 17.05 (+0.42)

Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis
PR Newswire - Thu Dec 18, 3:52PM CST
Aratana Therapeutics, Inc. (NASDAQ: PETX), a biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for companion animals, today announced positive results from its pivotal field study of AT-001 (Grapiprant), the company's innovative drug for treating pain in dogs with osteoarthritis. In the study, dogs receiving AT-001 demonstrated improvements in pain assessment scores that were statistically significant compared to placebo (p<0.05) at a once-daily oral dose. Aratana expects to commence commercialization upon FDA approval, which Aratana anticipates in 2016.
PETX: 17.05 (+0.42)

Aratana Therapeutics Initiates Pivotal Study for AT-003
PR Newswire - Tue Dec 16, 3:28PM CST
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today announced the initiation of the pivotal field effectiveness study for AT-003, the company's innovative drug for treating post-surgical pain in dogs licensed from Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX). AT-003 is an extended release injectable formulation of bupivacaine.
PETX: 17.05 (+0.42), PCRX: 92.09 (-1.79)

Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST

TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), FPRX: 26.12 (+0.07), ZFGN: 30.99 (+0.67), CRIS: 1.29 (+0.04), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)

Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 38.86 (+0.53), ZSPH: 43.93 (+1.77), AMRN: 0.99 (unch), OPHT: 44.93 (+1.06), AERI: 29.49 (+1.23), ASPX: 49.93 (-0.10), CNCE: 11.76 (+0.11), ICEL: 5.74 (-0.18), GWPH: 68.08 (+1.82), AUXL: 34.40 (+0.18), RTRX: 12.92 (+0.19), RCPT: 122.05 (+4.05), AAVL: 47.30 (-1.20), AKBA: 11.23 (-0.31), EXPR: 14.96 (+0.32), RARE: 45.17 (-0.56), ZGNX: 1.20 (+0.04), RLYP: 30.35 (-0.22), PETX: 17.05 (+0.42), ENTA: 49.04 (+0.06), RDUS: 37.17 (+0.11), CARA: 9.78 (+0.02), FLML: 17.01 (-0.98), ALIM: 5.43 (-0.06), ANIP: 55.24 (+1.79), ICPT: 151.49 (+5.85), RVNC: 16.65 (+0.42), POZN: 7.86 (+0.07), NDAQ: 48.74 (-0.40), FPRX: 26.12 (+0.07), CRIS: 1.29 (+0.04), ZFGN: 30.99 (+0.67), QLTI: 3.72 (+0.08), PCYC: 121.84 (+1.15), PTX: 9.05 (+0.28), CLDN: 18.54 (+0.85), RIGL: 2.22 (+0.02), HPTX: 21.91 (-0.08), AMPH: 11.74 (-0.09), INO: 9.11 (-0.09), VSAR: 22.25 (-0.11), FMI: 23.99 (-0.10), TBPH: 14.84 (+0.20), XLRN: 38.80 (+0.80), MGNX: 33.00 (+0.34), INSM: 15.29 (+0.15), ONTX: 3.82 (+0.06), ALDR: 25.67 (+0.43), SAGE: 38.13 (-0.75), KITE: 51.96 (+0.45), CGEN: 8.58 (-0.17), FOLD: 7.94 (+0.06), KPTI: 37.78 (+1.28)

Aratana Therapeutics to Present at the 2014 Animal & Dental Health Summit
PR Newswire - Fri Dec 05, 11:13AM CST
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing or acquisition, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, today announced that it will present at the 2014 Animal & Dental Health Summit, to be held December 11-12, 2014, at the Bank of America Merrill Lynch Conference Center in Boston, MA.
PETX: 17.05 (+0.42)

Aratana Therapeutics to Present at the 26th Annual Piper Jaffray Healthcare Conference
PR Newswire - Fri Nov 28, 9:52AM CST
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing or acquisition, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, today announced that it will present at the 26th Annual Piper Jaffray Healthcare Conference, to be held December 2-3, 2014, at the New York Palace Hotel in New York.
PETX: 17.05 (+0.42)

Aratana Therapeutics to Present at Jefferies Global Healthcare Conference
PR Newswire - Mon Nov 17, 1:12PM CST
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing or acquisition, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, today announced that it will present at the Jefferies Global Healthcare Conference, to be held November 19-20, 2014, at the Waldorf Hilton Hotel in Aldwych, London.
PETX: 17.05 (+0.42)

Aratana Therapeutics' (PETX) CEO Steven St. Peter on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 11, 1:29PM CST

PETX: 17.05 (+0.42)

Aratana beats 3Q profit forecasts
Automated Insights - Tue Nov 11, 4:11AM CST
KANSAS CITY, Kan. (AP) _ Aratana Therapeutics Inc. (PETX) on Tuesday reported a third-quarter loss of $10.1 million.
PETX: 17.05 (+0.42)

Notable earnings before Tuesday's open
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 4:30PM CST

DHI: 24.80 (-0.01), CST: 44.01 (+0.01), INSY: 41.52 (+0.51), QIWI: 20.88 (+0.36), OTIV: 1.71 (unch), PETX: 17.05 (+0.42), SABR: 20.39 (+0.07), ACM: 30.46 (+0.06)

Aratana Therapeutics beats by $0.06
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 4:23PM CST

PETX: 17.05 (+0.42)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

LASIK Cost Math Deserves a Careful Second Look Today

Updated Category News Views 114

Thirty years of lens purchases can become a nasty tab Contact-lens spending has a funny way of staying invisible until somebody stacks the receipts into one ugly pile. A new cost-of-vision analysis from the surgeon advisory board of BestLASIKSurgeons.com says the average American contact-lens wearer may spend between $22,500 and $30,000 on corrective eyewear across 30...

Continue Reading
Hexaware’s Seven-Year Client Signal Is Worth Watching

Updated Category News Views 38

Seven straight years of recognition is harder to shrug off than one shiny plaque on a corporate shelf. Hexaware Technologies announced on November 18, 2026 that it received the ISG Star of Excellence Award in the Client Champion category, marking its seventh consecutive year of recognition in that awards program. For investors following IT services, that is a...

Continue Reading
Spruce Spins Adrenyx En Route to Nasdaq in 2027

Updated Category News Views 114

New Frontiers: Adrenyx Biosciences Takes Shape Well, here's a new chapter in biotech drama. Spruce Biosciences, a name you might have tangled with if you're into tickers like NASDAQ:SPRB, just carved out a niche with the birth of Adrenyx Biosciences. The play? A separate company eyeing the endocrinology space, setting its sights on tackling congenital adrenal hyperplasia...

Continue Reading
Vertiv's 800 VDC Push Gives AI Builders More Choices

Updated Category News Views 217

Electricity is becoming the awkward roommate inside every serious AI buildout, and Vertiv is trying to move it out of the rack before it eats the whole house. The company has expanded its 800 VDC offering beyond the PowerDirect 5000 rack product introduced in May 2026, laying out systems for the rack, the AI compute pod, and the full data hall. For investors following...

Continue Reading
Philadelphia Firm Targets 100 Toys for Children This Holiday

Updated Category News Views 157

A hundred unopened toys can look modest on paper, yet that is exactly why this Philadelphia effort lands differently than the usual chest-thumping corporate charity chatter. van der Veen, Hartshorn & Levin has set a clear holiday target: collect 100 new, unwrapped toys for children in the Philadelphia area through the U.S. Marine Corps Reserve Toys for Tots program. No...

Continue Reading
Wonder Create: Democratizing Restaurant Creation

Updated Category News Views 123

Breaking Down Barriers in the Restaurant Industry It's been a long time since someone truly shook up the restaurant scene like this. Wonder Create is stepping in to turn anyone with a wild food idea into a bonafide restaurateur. We're not talking about the ol' franchising route here. We're diving straight into democratizing the culinary world. You seen something this bold...

Continue Reading
Sola's 11-Step Push Makes Salon Ownership Less Blind

Updated Category News Views 141

A pristine studio does not pay rent by itself. That is the uncomfortable little truth sitting underneath Sola Salons’ new 11-step roadmap for beauty professionals considering salon-suite ownership. The company is telling stylists, estheticians, nail technicians, massage therapists, and other independent operators to treat the move from commission work to ownership like...

Continue Reading
Texas Community Bancshares Adds a Special Dividend

Updated Category News Views 109

Nine cents is the whole message—for the moment Texas Community Bancshares has put a little extra cash on the table, declaring a regular quarterly dividend of $0.06 per common share and a special cash dividend of $0.03 per share. Together, holders get $0.09 per share, payable on or about December 15, 2026, provided they are shareholders of record when business closes on...

Continue Reading
Xailient Tops NIST for Real-World AI Face Recognition

Updated Category News Views 87

In a world where bigger ain't always better, Xailient's latest triumph at NIST's face recognition test has set them apart. On November 17, 2026, the U.S. National Institute of Standards and Technology (NIST) crowned Xailient as the leader in face recognition accuracy for on-device AI, leaving 105 others in the dust. This ain't your run-of-the-mill achievement—it shows...

Continue Reading
Hanon's BMW Thermal Win Matters Beyond the Trophy Case Today

Updated Category News Views 32

A 16-Kilogram Box Just Grabbed the Auto Supply Chain’s Attention Hanon Systems did not win these two 2026 PACE honors by polishing up some old hose-and-valve package. Its Highly Integrated Cooling Entity, or HICE, is aimed right at a stubborn electric-vehicle problem: keeping a vehicle’s thermal systems controlled without turning the architecture into a sprawling,...

Continue Reading

Top 5 Most Recently Viewed Articles

Gold's Surge and Euro's Stagnation Amid Economic Shifts

Updated Category News Views 261

Gold Gains Ground Amid Geopolitical Tensions Gold prices have recently shown an impressive rise, climbing 1.9% and breaking through the resistance level of $2,600. This rally followed a significant weekly decline in prices and reflects the market's reaction to ongoing geopolitical uncertainties. The surge in gold can be traced back to several influencing factors. One of...

Continue Reading
Teachable's Innovative Rebrand and Future Learning Vision

Updated Category News Views 209

Teachable's Innovative Rebrand and Future Learning Vision Teachable, a leader in online education, proudly announces a new visual identity and a striking product vision that redefines the learning experience for everyone. As the platform continues to evolve, the changes reflect a deep commitment to meeting the needs of today’s learners and educators. A New Identity for...

Continue Reading
Functionize Elevates Software Testing with Advanced AI Solutions

Updated Category News Views 169

Functionize Enhances Automation for Software Testing Automation Innovations Reshape Testing Using Natural Language Inputs to Create Reliable Tests and Streamline Complex Processes Across Enterprises Functionize, an innovative platform leveraging AI for software test case creation, has unveiled significant enhancements to its intelligent testing solutions. The recent...

Continue Reading
Anterix Inc. Delivers Strong Fiscal Performance This Quarter

Updated Category News Views 199

Anterix Inc. Highlights Its Fiscal Progress Anterix Inc. (NASDAQ: ATEX), based in Woodlang Park, has recently revealed impressive results for its second quarter of fiscal 2026. The company has filed its Form 10-Q, reflecting the financial performance for the three and six months leading to september 30, 2025. During this quarter, Anterix provided an update on its...

Continue Reading
10X Genomics Futures Brighten with New Single Cell Products

Updated Category News Views 80

10X Genomics Holds Steady with New Innovations 10X Genomics (NASDAQ: TXG) has received a reiterated Hold rating from TD Cowen, with a price target set at $20.00. This decision follows the company's announcement of plans to launch new Single Cell (SC) products during an industry event. The innovative products aim to provide cost-effective solutions focused on reducing...

Continue Reading